Information about Carbinson 
Each tablet contains 25 mg of carbidopa + 100 mg of levodopa Or 25 mg of carbidopa + 250 mg of levodopa.
Carbinson is indicated in the treatment of Parkinson's disease, post-encephalitic Parkinsonism, and symptomatic Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on Carbinson. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.
Dosage and administration: 
The optimum daily dosage of Carbinson must be determined by careful titration in each patient. 
Carbinson tablets are available in a 1:4 ratio of carbidopa to levodopa (Carbinson 25- 100) as well as 1:10 ratio (Carbinson 25 -250). 
Tablets of the two ratios may be given separately or combined as needed to provide the optimum dosage. 
Usual Initial Dosage: Dosage is best initiated with one tablet of Carbinson 25- 100 three times a day. This dosage schedule provides 75 mg of carbidopa per day. Dosage may be increased by one tablet every day or every other day, as necessary, until a dosage of eight tablets of Carbinson 25- 100 a day is reached. However, this will not provide an adequate amount of carbidopa for many patients.
Dosage may be increased by one tablet every day or every other day until a total of eight tablets (2 tablets q.i.d) is reached.
Storage conditions: 
Store at room temperature 25° c, away from light and moisture.
Carton box contains 20 Tablets for the two strengths.